10:25 AM EST, 11/24/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month price target by $20 to $90, based on 22.5x our FY 26 EPS estimate and in line with the company's three-year average forward P/E multiple. We raise our FY 25 and FY 26 EPS estimates by $0.58 to $3.80 and $0.34 to $4.00, respectively. After a +50% rally in just two months we believe shares trade near fair value thanks to a much better FQ3 and quicker-than-expected synergy execution on its recent acquisitions. GMED posted normalized FQ3 EPS of $1.18 vs. $0.83, $0.42 above consensus estimates on revenues of $769M vs. $626M and $31M above estimates. Revenues increased 22.9% as reported and 22.3% in constant currency. The company's base business (excluding Nevro) increased 7% to $670M, while net sales for its recently acquired Nevro products were $99M. FQ3 non-GAAP free cash flow increased 24% Q/Q to $214M. FQ3 operating income expanded over 1,000 bps Y/Y to 17.9% due to both synergy capture and operating leverage from the NuVasive merger and Nevro acquisition.